Nusano to Present at Jefferies Radiopharma Innovation Summit
2024-04-10
Nusano to Present at Jefferies Radiopharma Innovation Summit
VALENCIA, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, today announced it will attend and present at Jefferies Radiopharma Innovation Summit in New York City on Thursday, April 11, 2024.
In his presentation, Nusano CEO Chris Lowe will provide an update on the company’s commercialization plans, including programs to make lutetium-177 and actinium-225 available on a commercial scale in 2025. Nusano management will also be available for 1-on-1 meetings. To request a meeting, qualified investors should contact their Jefferies representative or email info@nusano.com.
What:Company PresentationWho:Chris Lowe, Chief Executive OfficerWhen:Thursday, April 11, 2024
3:00 p.m. ET
About Nusano
Nusano is a privately held company committed to bringing stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market. Nusano’s proprietary ion source is smaller and more efficient than existing production methods. This results in significantly greater yields and allows for the simultaneous manufacturing of multiple radioisotopes. Nusano’s technologies will supply the fight against cancer and support diagnostic and therapeutic radiopharmaceutical development. The company’s state-of-the-art production facility opens Q1 2025 in West Valley City, Utah. For more, please visit www.nusano.com.
Contacts
Media: Scott Larrivee, Nusano, 608-345-6629, scott.larrivee@nusano.com
Investor Relations: Joyce Allaire, LifeSci Advisors, LLC, 212-915-2569, jallaire@lifesciadvisors.com
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。